Healthcare -
Biotechnology - NASDAQ - US
$ 2.44
-5.47 %
$ 93.5 M
Market Cap
-1.46
P/E
1. INTRINSIC VALUE
Balance Sheet
Orchestra BioMed Holdings, Inc.
| Current Assets | 69.2 M |
| Cash & Short-Term Investments | 66.8 M |
| Receivables | 92 K |
| Other Current Assets | 2.27 M |
| Non-Current Assets | 7 M |
| Long-Term Investments | 2.5 M |
| PP&E | 3.49 M |
| Other Non-Current Assets | 1.02 M |
| Current Liabilities | 16.2 M |
| Accounts Payable | 5.13 M |
| Short-Term Debt | 550 K |
| Other Current Liabilities | 10.5 M |
| Non-Current Liabilities | 27 M |
| Long-Term Debt | 14.3 M |
| Other Non-Current Liabilities | 12.7 M |
EFFICIENCY
Earnings Waterfall
Orchestra BioMed Holdings, Inc.
| Revenue | 2.64 M |
| Cost Of Revenue | 204 K |
| Gross Profit | 2.43 M |
| Operating Expenses | 66.7 M |
| Operating Income | -64.3 M |
| Other Expenses | -3.28 M |
| Net Income | -61 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Orchestra BioMed Holdings, Inc.
| Net Income | -61 M |
| Depreciation & Amortization | 308 K |
| Capital Expenditures | -289 K |
| Stock-Based Compensation | 10.6 M |
| Change in Working Capital | -765 K |
| Others | -3.42 M |
| Free Cash Flow | -50.8 M |
Wall Street Analysts Price Targets
Orchestra BioMed Holdings, Inc.
Wall Street analysts predict an average 1-year price target for OBIO of $12 , with forecasts ranging from
a
low of
$12 to a high of $12 .
OBIO Lowest Price Target
Wall Street Target
12 USD
391.80%
OBIO Average Price Target
Wall Street Target
12 USD
391.80%
OBIO Highest Price Target
Wall Street Target
12 USD
391.80%
4. DIVIDEND
ANALYSIS
OBIO does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Orchestra BioMed Holdings, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
226 K USD 2
9-12 MONTHS
0 USD 0
Bought
276 K USD 1
0-3 MONTHS
48 K USD 2
3-6 MONTHS
47.9 K USD 1
6-9 MONTHS
74.5 K USD 2
9-12 MONTHS
7. News
Orchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure
NEW HOPE, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced continued expansion of its global intellectual property (IP) estate supporting its proprietary AVIM therapy pipeline (formerly known as Cardiac Neuromodulation Therapy or “CNT”). Over the past 12 months, the Company has secured 10 new patents related to treatment of hypertension. The Company has also secured a total of 17 patents covering application of the technology for treatment of heart failure, significantly expanding the reach of its IP platform.
globenewswire.com
- 1 week ago
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Orchestra BioMed Holdings, Inc. (OBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com
- 2 weeks ago
Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon
Orchestra BioMed's Virtue ® Sirolimus AngioInfusion Balloon™ (“Virtue SAB”) is the only non-coated drug-eluting balloon system under clinical investigation worldwide and has been awarded multiple FDA Breakthrough Device Designations The Virtue Trial will be the first U.S. IDE head-to-head randomized evaluation of a sirolimus-eluting balloon versus a commercially available paclitaxel-coated balloon (AGENT™) for the treatment of coronary in-stent restenosis (“ISR”) Robust non-inferiority trial is designed to provide a clear pathway to regulatory approval as well as potentially showcase clinical advantages of Virtue SAB With the amended IDE approved by the FDA, Orchestra BioMed is currently targeting initiation of the Virtue Trial during the second half of 2025 NEW HOPE, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that the U.S. Food and Drug Administration (“FDA”) has approved its Investigational Device Exemption (“IDE”) amendment to initiate an updated design of the Company's planned Virtue SAB in the Treatment of Coronary ISR Trial (“Virtue Trial”).
globenewswire.com
- 3 weeks ago
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
NEW HOPE, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will participate in multiple upcoming institutional investor conferences.
globenewswire.com
- 3 weeks ago
Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting
FDA recently granted Breakthrough Device Designation to AVIM therapy for use in patients with uncontrolled hypertension at increased cardiovascular risk HRS Satellite Symposium will feature leading experts in electrophysiology, hypertension management and heart failure Presentations will detail clinical results from prior studies demonstrating AVIM therapy's ability to immediately, substantially and persistently reduce systolic blood pressure, as well as improve cardiac function Symposium will also feature presentation on the BACKBEAT global pivotal study Orchestra BioMed is currently enrolling in strategic collaboration with Medtronic, plc (NYSE: MDT) NEW HOPE, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced it will host an industry-sponsored satellite symposium at the Heart Rhythm Society (“HRS”) 2025 Annual Meeting, taking place April 24–27, 2025, in San Diego, California featuring recent advancements in the Company's atrioventricular interval modulation (“AVIM”) therapy program.
globenewswire.com
- 3 weeks ago
Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy
NEW HOPE, Pa., April 22, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Breakthrough Device Designation (“BDD”) for atrioventricular interval modulation (“AVIM”) therapy.
globenewswire.com
- 4 weeks ago
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q4 Loss, Lags Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) came out with a quarterly loss of $0.43 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.37 per share a year ago.
zacks.com
- 1 month ago
Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update
NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update.
globenewswire.com
- 1 month ago
Orchestra BioMed to Present at Upcoming Investor Conferences
NEW HOPE, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at multiple upcoming investor conferences.
globenewswire.com
- 2 months ago
Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board
NEW HOPE, Pa., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the appointment of Vivek Reddy, M.D., as Executive Chairman of the Company's BACKBEAT Study Steering Committee and Chairman of its Bioelectronic Therapies Scientific Advisory Board. In these roles, Dr. Reddy will provide critical leadership in continuing to execute the BACKBEAT global pivotal study and further develop scientific evidence and clinical value for the Company's bioelectronic therapies portfolio.
globenewswire.com
- 3 months ago
Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference
NEW HOPE, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced a late-breaking oral presentation of data on the benefits of atrioventricular interval modulation (“AVIM”) therapy on patients with diastolic dysfunction at the Technology and Heart Failure Therapeutics (“THT”) 2025 Conference in Boston, Massachusetts. The retrospective analysis of data from the MODERATO II study demonstrated that AVIM therapy significantly improved echocardiographic (“Echo”) markers of diastolic dysfunction, an important component in the development of heart failure, in hypertensive patients.
globenewswire.com
- 3 months ago
Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors
NEW HOPE, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the appointment of Christopher Cleary to its Board of Directors as an independent member, effective as of January 30, 2025. Mr. Cleary brings over three decades of experience in corporate development, mergers, acquisitions, strategic investments and structured R&D collaborations, having significantly impacted the medical technology industry through his strategic leadership and visionary approach.
globenewswire.com
- 3 months ago
8. Profile
Summary
Orchestra BioMed Holdings, Inc. OBIO
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 93.5 M
Dividend Yield
0.00%
Description
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Contact
150 Union Square Drive, New Hope, PA, 18938
https://orchestrabiomed.com
IPO
Date
Aug. 4, 2020
Employees
70
Officers
Dr. Hans-Peter Stoll M.D., Ph.D.
Chief Clinical Officer
Mr. Darren R. Sherman
Founder, President, Chief Operating Officer & Director
Mr. Bob Laughner
Senior Vice President of Regulatory & Quality
Mr. Andrew Lawrence Taylor M.B.A.
Chief Financial Officer
Dr. Yuval Hay Mika D.Sc, Ph.D.
GM & Chief Technology Officer of Bioelectronic Therapies
Dr. Avraham Matityahu Fischer M.D.
Senior Vice President of Medical Affairs & Innovation
Mr. Juan Lorenzo
Senior Vice President of Product Development
Mr. William Reed Little
Executive Vice President of Corporate Development & Strategy
Mr. Mark Pomeranz
GM & Executive Vice President of Interventional Therapies
Mr. David P. Hochman
Founder, Chairman of the Board of Directors & Chief Executive Officer